Lentiviral vectors (LVs) offer the advantages of a large packaging capacity, broad cell tropism or specific cell-type targeting through pseudotyping, and long-term expression from integrated gene cassettes. However, transgene integration carries a risk of disrupting gene expression through insertional mutagenesis and may not be required for all applications. A non-integrating LV may be beneficial in cases in which transient gene expression is desired. Several recent publications outline the development and initial biological characterization of such vectors. Here, we discuss the potential applications and new directions for the development of integration-defective LVs.
Introduction
Lentiviral vectors (LV) are an important class of gene transfer vectors. LV have a large packaging capacity (410 kb transgene cassette 1, 2 ) and envelope glycoprotein pseudotyping achieves broad or specific tropism as necessary. These vectors are also associated with low immunogenicity. Importantly, they transduce mitotically quiescent cell types, including many relevant targets for gene transfer. One of the greatest benefits of LVs is their ability to integrate a transgene copy into target cell chromosomes, allowing for long-term expression. However, this process carries finite risks of detrimental insertional mutagenesis, prompting examination of alternatives to vector-mediated integration.
LV transduction biology
After vector internalization and reverse transcription in the cytoplasm, the vector double-stranded DNA is incorporated into the pre-integration complex. A critical component of the integration complex is viral integrase (IN), a 32-45 kDa protein, [3] [4] [5] [6] [7] which catalyzes viral DNA integration into the host genome ( Figure 1 ). [8] [9] [10] Once the integration complex reaches the nucleus, IN mediates integration between vector and host DNA.
Before nuclear translocation, 4, 11, 12 IN catalyzes the removal of two nucleotides from the 3 0 end of the reverse-transcribed genome at an invariant CA dinucleotide. 9, 10, 13 This 3 0 -processing forms hydroxyl groups necessary for integration. 9, 10, 14 IN then facilitates strand transfer through a one-step mechanism that both induces a staggered break in the phosphodiester bonds of the target DNA and joins a single vector DNA end to the target DNA through a transesterification reaction. 11, 14, 15 Once both vector DNA ends are attached, host enzymes repair the resulting gapped intermediate, generating an integrated provirus ( Figure 2) . 10, 14, 16 Although integration is generally described as the specific end point of lentiviral gene transfer, DNA episomes are also generated by lentiviruses and their derived vectors. 15, 17, 18 Among these, the linear DNA episome is the precursor to the integrated provirus ( Figure 2) . 11, 15, 19 Two types of circular episomes with intact viral coding regions are also produced. Homologous recombination (HR) within the LTRs generates a circular episome with a single LTR (1-LTR circle). 15, 17 In addition, ligation of nicks in the circular DNA intermediates during the final stage of reverse transcription also results in 1-LTR circle episome formation. 15, 20 Non-homologous end joining of the linear episome results in a circular episome with two adjacent LTRs (2-LTR circle) (Figure 2) . 15, 17, 21 Generally, 1-LTR circles are more prevalent than 2-LTR circles, but ratios vary. 17, 18, [22] [23] [24] Both 1-and 2-LTR episomes can express proteins because the genome or transgene remains intact. 25, 26 IN can also auto-integrate within the viral DNA itself, but the disruption of the viral coding region generally renders the resulting products inactive. 17, 27 Episomes do not persist in dividing cells because they are not integrated and lack an origin of replication (ORI). It was originally hypothesized that 1-and 2-LTR episomes were rapidly degraded as shown by PCR analysis of 2-LTR circles present in peripheral blood mononuclear cells from HIV infected patients. 18 However, subsequent studies determined that the apparent half-life of these episomes correlated with the rate of cell division. 23, 28 Therefore, viral episomes are stable and the observed loss occurred from dilution of the episomes during cell replication.
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LV integration
As LVs introduce a permanent transgene copy into the host genome, they achieve persistent gene expression. 15, 19, [29] [30] [31] This may correct a monogenic recessive disorder. However, LV integration is inherently mutagenic and could induce detrimental side effects depending on the specific host gene disrupted. For instance, the activation of a protooncogene or disruption of a tumor suppressor gene could lead to the development of cancer. Retroviral integration site selection was initially hypothesized to be random, based largely on in vitro studies. 6, 32 However, the risks of insertional mutagenesis were highlighted during the X-SCID retroviral gene therapy trials. [33] [34] [35] [36] [37] Unexpectedly, five patients developed T-cell such as leukemia as a result of vector treatment. 33, 34, 36, 37 According to the model of site selection at the time, multiple oncogenic events should have been exceedingly rare. Extensive integration site mapping studies subsequently showed that retroviral integration site selection is not random and varies between gammaretroviruses, lentiviruses and other classes of integrating viral and non-viral vectors.
Studies show that gammaretroviruses preferentially integrate in 5 0 flanking regions of genes near transcription start sites, increasing the possibility of affecting nearby gene expression. 32 Unlike gammaretroviruses, LV do not exhibit an increased integration site preference for 5 0 flanking regions and avoid CpG islands, a characteristic feature found near transcription start sites. 32 Instead, this vector class integrates across the entire transcriptional unit. 32, [38] [39] [40] [41] A recent study showed that LV with chimeric gammaretroviral LTRs were still significantly less genotoxic than gammaretroviral vectors. 42 Therefore, LV site selection preferences are distinct from gammaretroviral vectors and may be less genotoxic for therapeutic uses. Though the probability of aberrant gene activation or disruption are less likely after LV integration, insertional mutagenesis risks must be considered for clinical applications. 2, 30, 33, 34, 43 One approach to circumvent detrimental insertional mutagenesis risks is the generation of a vector with properties of specific 'safe' site integration. 44, 45 However, permanent transgene expression is not necessary or desirable in all applications. An alternative to a permanently integrated transgene is transient expression from an integration-defective LV vector (termed IDLV, also INdef, IN-or NILV). Non-integrating gammaretroviral vectors have been described, 46 but because they cannot transduce non-dividing cells, several clinically relevant cell types are not effectively targeted. However, LV transduce slowly dividing cell types; therefore, episomal vector DNA is diluted slowly and persists. [47] [48] [49] Several reports have detailed the production of HIV IDLVs. 13, 22, 44, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] In addition, feline immunodeficiency virus (FIV) IDLVs are also described. 48 Integrase-defective LVs: progress and applications MB Banasik and PB McCray Jr studies ( Figure 1) . 12, 62 The N-terminal domain contains an HH-CC zinc-finger binding domain that primarily binds viral DNA 5, 63, 64 and facilitates required IN multimerization. 65, 66 The C-terminal domain is the least conserved retroviral IN domain 5, 67, 68 and binds nonspecific target DNA. 63, 69 The IN core domain contains the D-D35E catalytic amino-acid triad motif, comprised of amino-acids D64, D116 and E152 in HIV. 6, 70 These residues are absolutely conserved among retroviral INs and are similar to other transposase active sites. 3, 4, 12, 63, [70] [71] [72] Mutations within IN often form IDLVs. Class I mutations refer to specific integration deficiencies that leave other viral processes intact. Class II mutations impair multiple stages of the viral life cycle. 48, 72 Class I IN mutations are more suitable than class II mutations for generating IDLVs, because the pleotropic effects associated with class II mutations make them unsuitable for vector development. A variety of point mutations produce IDLVs and affect different stages of the integration process (Figures 1 and 2 ).
The most commonly used IDLV mutations introduce a missense amino acid in the catalytic triad ( Figure 1 ). An alteration in any of these residues inactivates the catalytic properties of IN. Of these potential mutation target sites, D64 is most commonly altered, 13, 22, 44, [48] [49] [50] [51] [52] [53] [55] [56] [57] 60 but mutations to D116 have also been reported. 51, 54, 58, 59 Additional mutations affect IN DNA binding, linear episome processing or IN multimerization ( Figure 2 ). IN must successfully bind both vector DNA and genomic DNA to support integration. Vector DNA binding is impaired by altering Q148. 50 By mutating the RRK(262-264) motif in the C-terminal domain, IN fails to bind target genomic DNA. 47, 50, 73 Both N120 and W235 are also implicated in genomic DNA binding and generate IDLV mutations when altered. 50 In addition, mutating the K264/K266/K273 triad impairs both target DNA binding and strand transfer. 47, 50 As IN multimerization is required for proper function, blocking mutations, such as those to H12, also generate IDLVs. 51 For successful IN-mediated integration to occur, the vector LTRs are cleaved at an invariable CA dinucleotide. Mutations in these LTRs (att mutants) also render the vector integration deficient.
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IDLV biology
Although IDLVs could be an important alternative to either integrating LVs or other non-integrating vectors, most envisioned IDLV applications require effective levels of transgene expression. The biological differences and similarities of IDLVs and integrating LVs were compared in several independent studies. Primary areas of focus include transgene expression and the level of integration deficiency.
Early HIV IDLVs were ineffective at transgene expression. 25, 61, 74, 75 In vivo brain injections comparing expression from HIV LV and D64V IDLV found no transgene expression from the IDLV. 74 A later report examined the potential efficacy of HIV D64V IDLV in liver transduction experiments and again no expression was observed. 75 Retinal injections of an FIV IDLV also yielded no transgene expression. 61 From these early experiments, integration was hypothesized to be required for LV expression, despite conflicting evidence from non-integrating lentiviral infections 26, 72, 76 and other non-integrating viruses.
After confirmation of lentiviral episomal persistance, 23 ,28 the potential of IDLVs was further examined. The first successful IDLVs exhibited roughly equivalent gene expression levels in growth arrested cells from both HIV-and FIV-derived vectors. 48 Some later reports also indicated equivalent levels of gene expression from IDLVs. 13, 49 In general, LV and IDLV expression equivalency was derived from the percentage of cells transduced as opposed to more sensitive means, such as measuring total protein production. 13, 48, 49 Other publications suggested that IDLVs do not support levels of gene expression equivalent to integrating LVs. An early IDLV report comparing both the percentage of cells transduced and GFP mean fluorescence intensity observed a slight reduction of IDLV efficiency. 58 Later work using similar methodologies confirmed that while IDLVs had similar transduction percentages, GFP fluorescence values were suppressed. 22, 47, [50] [51] [52] 58, 59 The level of reduction varies between reports, from approximately one half 50, 52 to one tenth that of integrating LV. 22, 51 Observations that an IDLV generated reduced humoral immune responses may also indicate reduced protein expression. 54 The results from our laboratory indicate that FIV IDLV luciferase reporter transgene expression is B10-fold less than a matched integrating FIV LV control (MB Banasik and PB McCray, unpublished observation).
A recent study by Bayer et al. 22 focused extensively on the differences in gene expression achieved from HIV IDLVs. Initially, the authors wished to clarify discrepancies from early, non-functional HIV IDLV reports. 61, 74, 75 These initial IDLVs contained full-length LTRs, as opposed to U3 deleted, self-inactivating (SIN) LTRs. The authors hypothesized that the HIV full-length LTRs contain cis acting regulatory elements that prevented episomal transgene expression. To address this, LVs and IDLVs with differing lengths of LTR SIN deletions were compared for transduction and transgene expression efficiency. The LTR length did not affect the roughly equivalent percent transduction by LVs or IDLVs. However, the level of transgene expression was altered in IDLVs. A longer SIN LTR deletion improved both GFP and luciferase transgene expression. Even so, HIV IDLVs yielded significantly reduced gene expression. The inclusion of a long SIN deletion improved the IDLV mean fluorescence and luciferase expression to B10-15% of a integrating LV. 22 Therefore, despite early accounts of equivalent levels of gene expression from IDLVs, mounting evidence suggests that lentiviral episomes are a weaker template for effective gene expression.
Most reports of IDLVs note similar vector titers compared with integrating LVs. The most common titering method is a p24 ELISA assay, 13, 50, 52, 53, 57 with additional comparisons of RT activity, 48, 54 vector genomes 53 and transducing units as determined by a visual marker. 13, 22, 50 Three groups report lower transduction efficiency in IDLVs as compared with LVs when normalized to p24 content. 47, 50, 58, 59 Vargas et al. 58, 59 reported B25% reduction in transduction from IDLVs as compared with integrating LVs. Philippe et al.
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reported a 10-fold decrease in TU/ng p24 in IDLVs, and Apolonia et al. 50 reported a fivefold decrease using similar methods. Although these findings may reflect the
earlier noted lower levels of transgene expression, they may also represent a deficiency in initial vector particle formation. Titer differences may also vary depending on the lentiviral backbone. We have reproducibly observed a 10-fold decrease in FIV IDLV titers when quantified by transducing units, viral genomes or RT activity (MB Banasik and PB McCray, unpublished observation). Although LVs and IDLVs should transduce similar cell types, endogenously expressed proteins may further influence transgene expression from unintegrated episomes. IDLVs had different expression levels in various T-cell-derived cell lines and primary cells. 77 IDLVs also failed to express in the corpus callosum and expression was reduced in astrocytes as compared with integrating LVs. 22 Although these are limited examples, they raise the possibility that endogenous factors may influence expression from non-integrated episomes.
IDLVs lack viral protein-mediated integration. 4 Although the integration frequency of IDLV is greatly reduced, background integration that occurs at a similar frequency as naked DNA may be unavoidable.
Persistence of expression from IDLV
Although IDLV episomal DNA expresses a transgene, this vector form dissipates with cell division. 23, 28 The duration of transgene expression varies depending on how rapidly transduced cells turn over. The length of this expression has been characterized in a number of in vitro and in vivo settings.
Expression duration in cell culture systems is highly transient because of rapid cell turnover. 22, 47, 51 If cell division is decreased, expression can be maintained for a greater time. IDLV-mediated expression was short lived in dividing CRFK and HT1080 cells. However, cell growth arrest before IDLV transduction enhanced expression duration. 48 A similar duration increase was observed between dividing and non-dividing C2C12 cultures. 50 Alternatively, if the transgene cassette carries a viral ORI, IDLV transgene expression persists if necessary trans proteins are supplied. By including the SV40 ORI in IDLVs, transgene expression lasted 56 days, the final time point examined, in the SV40 T-antigen containing 293T cell line. This contrasted to parallel transductions in 293 cells, with no SV40 T-antigen, in which transgene expression was short lived. 58 In vivo studies have primarily focused on the transduction of slowly dividing tissue populations to maximize IDLV expression duration. In all cases, transgene expression remained constant throughout the observed experiment. An exception was the ex vivo transduction of hematopoietic stem cells, a rapidly dividing population, in which expression was noted for 1 month. 13 Both muscle and dendritic cells supported IDLV expression for up to 3 months. 50, 52 Several studies show efficient IDLV expression in the brain, with the longest duration examined for 4 months. 22, 47, 49, 56 The longest IDLV brain transduction report was particularly notable because the vector was delivered in utero. 56 The same report also followed transgene expression in the spinal cord for 14 days, but did not examine gene expression duration further. 56 Liver transduction with IDLV vectors was observed for as long as 6 months. 22, 50 To date, the longest IDLV study was in murine retina. After transduction, efficient GFP expression was observed in the retinal pigment epithelium for up to 9 months. 49 
INdef vector therapeutic applications
As IDLV-mediated transgene expression is long lasting in slowly dividing cell types, 22, 47, 49, 50, 56 non-integrated, corrective gene expression may be achieved in these tissue types. Both mouse and rat models of retinitis pigmentosa had visual improvement, as shown by electroretinography, after transgene appropriate IDLV delivery. 49 Phenotypic correction was stable for 8 weeks after injection with no loss of improvement in IDLVtreated animals. 49 Although IDLVs lack viral protein-mediated proviral insertion, several reports have used IDLVs as a platform for transgene integration through alternate pathways. One option is to use episomes as templates for HR for either gene-specific correction or 'safe site' integration. Okada et al. used a neomycin resistance transgene cassette flanked by 'arms' complementary to the calmegin gene to generate mouse ES cells with a site-specific transgene insertion. Several neomycin resistant ES cell lines were established after IDLV treatment, and a small proportion had gene-specific integration (0.83%). 55 Gene targeting from IDLVs was less efficient than more traditional plasmid electroporation. The authors hypothesized that vector DNA incorporation into the integration complex may hinder access to endogenous HR components. 55 Two other groups have also studied targeted integration through HR, but induced doublestranded breaks, which improve HR frequency. By introducing two IDLVs carrying either an ISce-I restriction enzyme expression cassette or a non-expressed lacZeGFP HR template, Cornu and Cathomen 51 reported sitespecific targeting and correction of a disrupted lacZeGFP gene. More significantly, Lombardo et al. 44 used IDLVs expressing zinc-finger nucleases to induce sitespecific double-stranded breaks. The authors primarily used a three IDLV transduction protocol, in which the vectors expressed one of the two necessary zinc-finger nucleases or carried the donor template. Using this method, successful gene correction was observed at the IL2RG locus. In addition, site-specific integration into the CCR5 locus targeted 50% of transduced cultured cells and 5% of human ES cells. 44 The CCR5 locus is hypothesized to be 'safe' for targeted integration because individuals homozygous for null mutations in the gene have no apparent health detriments. 44, 79 More recently, Lombardo et al. reported evidence that targeted insertion Integrase-defective LVs: progress and applications MB Banasik and PB McCray Jr of gene cassettes at the CCR5 locus results in aberrant expression of nearby endogenous genes and lower levels of integrated transgene expression, as compared with the AAVS1 locus. These preliminary results suggest that targeted integration at the CCR5 locus may not be as desirable as earlier envisioned. 80 Additional studies should further clarify this situation.
IDLVs may also serve as a platform for DNA transposon system delivery and expression. By including necessary cis elements in the transgene cassette, vector episomes can serve as appropriate templates for transposon-mediated gene addition. An IDLV expressing the yeast Flp recombinase conferred site-specific integration in an engineered human cell line. 53 By including Flp recombinase targets in a transgene cassette with a hygromycin-B construct lacking the ATG start codon, the authors screened targeted integrations in 293 cell lines that contained matching Flp recombinase targets sites downstream of a functional promoter and ATG codon. After dual IDLV transduction with Flp and the faulty hygromycin-B cassette, hygromycin-B resistant colonies were recovered (58±6 colonies per 7 Â 10 5 cells transduced), though at a much lesser efficiency than when integrating LV or plasmid expression of Flp were used. 53 Two recent reports described Sleeping Beauty (SB) transposase-mediated transposition when delivered using an IDLV. 57, 60 Unlike retroviral integration, SB transposition shows little preference for specific genomic regions. 57, 60 Both studies constructed two IDLVs, one expressing a hyperactive SB transposase and a second containing a transposable element with a drug resistance transgene cassette and necessary inverted repeats. Integration site analysis in drug resistant colonies revealed that cells transduced with the dual IDLVs showed an integration pattern similar to SB, and dissimilar from LV integration preferences (87 sites 57 and 119 sites 60 analyzed). Furthermore, no viral-derived elements (that is LTRs) were integrated with the transposon cassette. 60 Therefore, using IDLVs as platform for transposon delivery could reduce the risk of insertional mutagenesis by disfavoring transgene insertion in gene coding regions.
IDLVs also show promise for suicide gene therapy applications in virally transformed cancers. As discussed earlier, effective episomal replication occurred in the SV40 T-antigen expressing 293T cell line if the SV40 ORI was included in the transgene cassette. 58 Extending these results, a later study used the thymidine kinase suicide gene to render cells sensitive to ganciclovir treatment. 59 In IDLV transduced 293T cells, ganciclovir treatment was cytotoxic even 4 weeks post transduction because of nonintegrated lentiviral episome replication. 59 Although these studies used SV40 transformed cells, other viruses, such as the human papilloma virus and Epstein-Barr virus, could be targeted if their specific ORIs were included in the transgene cassette. 59 As IDLV expression is inherently transient, it may be ideal for vaccines. Selected viral or bacterial genes could be expressed, eliciting a protective immune response. Purified, plasmid-free IDLV vaccine vectors offer alternatives to plasmid DNA vaccines. The bacterial plasmid backbone and drug resistance genes contain many CpG sequences, which are prone to silencing and have been implicated in transient and low levels of transgene expression. [81] [82] [83] Minicircle plasmid technology can remove these undesirable bacterial sequences, but protocols for clinical grade preparations are still in their infancy. 83 Negri et al. 54 transduced BALB/c mice with an IDLV expressing HIV-1 gp120. After a single dose, robust cellular and humoral immune responses were detected in IDLV-treated animals for up to 90 days, the limit of the experiment. These results were a promising proof-ofprinciple for using IDLVs as vaccines, but efficacy testing was limited to quantification of immune response and not expanded to viral challenge. Recently, Coutant et al. These results illustrate the potential for IDLV vaccine applications.
Future directions
IDLVs show promise for achieving gene expression without integration, preserving some benefits of LVs, whereas reducing the potentially detrimental risk of insertional mutagenesis. Numerous reports support the ability of these vectors to confer long-term gene expression in slowly dividing cell types for potentially corrective gene expression. These reports also highlight additional applications of these vectors as delivery platforms for alternate integrative pathways, suicide gene therapy and vaccines. As discussed below, several areas for further research remain.
Earlier reports have noted lower gene expression levels from IDLVs, 22, 47, [50] [51] [52] 58, 59 presumably because episomes are not as effective as chromosomal vector proviruses. The mechanism for this difference between episomal and vector provirus transgene expression is currently unknown. As LVs integrate into transcriptionally active regions, local chromatin architecture and transcription factor-binding sites may aid expression. As episomes are unintegrated, these regional features are lacking. Similarly, various trans activating factors are hypothesized to affect episome expression and the prevalence of these factors may vary among target cell type. 22, 77 Although identification of these trans acting factors may prove difficult, knowledge of such elements could improve IDLV design by several means. These include ensuring that desirable trans acting factorbinding sites are retained, incorporating additional binding sites to increase expression efficiency, and focusing on IDLV development of LV backbones with favorable trans acting factor binding. Identification of such trans acting factors may also suggest cell and tissue targets with favorable levels of expression.
In addition, increased in vivo testing of IDLVs would be beneficial. Though LVs and IDLVs should transduce similar cell profiles when pseudotyped equivalently, differences in cell-type transduction in the brain have been noted. 22 Although this may be a unique result, it would be interesting to learn if any other cell transduction differences occur after IDLV transduction. The
Integrase-defective LVs: progress and applications MB Banasik and PB McCray Jr majority of in vivo testing has focused on longitudinal studies of IDLV expression of a marker transgene. 22, 47, 49, 50, 52, 56 As reviewed above, limited studies show potential applications for corrective gene expression or vaccines. These reports indicate a favorable profile for IDLV because of the sustained visual correction or protective immunity achieved after administration of a single vector dose. 49, 52, 54 Therapeutic gene expression studies could be expanded to other tissue types with robust INdef vector expression. IDLV delivery of non-viral integration platforms, such as zinc-finger nucleases-mediated HR or transposase-mediated integration, show promise in vitro. 44, 57, 60 It would be interesting to translate these procedures in vivo, especially in tissue types inaccessible to plasmid delivery. [84] [85] [86] IDLVs that are pseudotyped with a cell-type specific envelope glycoprotein could be systemically or topically delivered, bypassing the need for direct tissue injection. Not all cell types are easily transfectable, limiting the usefulness of plasmid-based transgene expression in some settings. 87 By harnessing the entry properties of viral vectors, the inefficiencies of plasmid delivery can be overcome. The potential for suicide gene therapy of virus transformed cells was shown in vitro with SV40 altered cells. 59 Not only would it be informative to test this system in vivo, it would also be of interest to confirm that other transformative viruses could be targeted.
In conclusion, IDLVs represent a class of novel viral vectors with several established and emerging applications. These vectors support lower levels of gene expression, and efforts should be made to identify potential expression limiting trans acting factors and to boost episomal gene expression. A number of potential applications have been shown for IDLVs, but further in vivo testing is required to show the utility of these techniques.
